Age-Related Macular Degeneration Market Size, Epidemiology, Treatment Trends, and Forecast to 2035

The age-related macular degeneration market reached a value of USD 10.3 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 12.2 Billion by 2035, exhibiting a growth rate (CAGR) of 1.61% during 2025-2035.

The market for age-related macular degeneration (AMD) in the year 2025 is growing gradually because of the increasing geriatric population, enhanced diagnostic techniques, and formulation of newer treatments. AMD is an irreversible eye disorder that targets the center of the retina, which is known as the macula, responsible for clear and precise vision. It is among the prime reasons for loss of sight in individuals who are 50 years and older, and the increase in aging populations all over the world is propelling the demand for successful AMD treatment.

One of the most important 2025 trends is the emphasis on long-acting drug delivery and combination treatments. Pharmaceutical firms are making investments in extended-release forms of anti-VEGF medications to decrease the number of injections necessary, thereby increasing patient compliance. New treatments are also being designed that treat both dry and wet AMD more effectively, such as gene therapies and regenerative medicine-based treatment methods like stem cell therapies.

Request for a sample of this report: https://www.imarcgroup.com/age-related-macular-degeneration-market/requestsample

The rise in retinal imaging and diagnostics will enable more rapid and accurate diagnoses of AMD. Optical coherence tomography (OCT) will remain a common and mentioned that eye care providers will be able to supervise the disease's progression and response to treatment 'in real time'. The role of artificial intelligence (AI) in screening programs will continue to expand as a means to assess retinal scans for early signs of macular degeneration especially in remote areas with limited access to ophthalmologists.

The sector is predominantly influenced by rates of AMD. As average life expectancy continues to increase with more people living longer into their 70s and 80s, numbers will continue to rise. Risk factors related to lifestyle, such as smoking, diet and lack of exercise, are also contributing factors to these increased rates of AMD. The increased burden has prompted health officials and policymakers to increase funding for early intervention and public health promotion of the risk factors, as well as encouragement to have an annual eye exam.

Ask the Analyst for Customization and Get Full Insights with TOC: https://www.imarcgroup.com/request?type=report&id=7911&flag=E

This report also provides a detailed analysis of the current age-related macular degeneration marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Competitive Landscape With Key Players:

The competitive landscape of the age-related macular degeneration market has been studied in the report with the detailed profiles of the key players operating in the market.

Novartis AG
Genentech USA, Inc.
Bayer AG
Neuraclegenetics
OliX Pharmaceuticals, Inc.
Ocular Therapeutix, Inc.
Sanofi

IMARC Group Offers Other Reports:

Acute Kidney Injury Market: https://www.imarcgroup.com/acute-kidney-injury-market

Anal Fistula Market: https://www.imarcgroup.com/anal-fistula-market

Bacterial Pneumonia Market:https://www.imarcgroup.com/bacterial-pneumonia-market

Bladder Cancer Market: https://www.imarcgroup.com/bladder-cancer-market

Breast Cancer Market: https://www.imarcgroup.com/breast-cancer-market

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.

IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.